Xilio Therapeutics, Inc. - 8-K Filing
Xilio Therapeutics reported Q1 2026 financial results with $150.3 million in cash, a net loss of $9.5 million (vs. $13.3M YoY), and collaboration revenue of $12.6 million driven by AbbVie and Gilead agreements. The company achieved an IND-related milestone under its AbbVie deal for $6.0 million and extended cash runway into early 2028. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $XLO